/lifesciences?utm_source=rss&utm_medium=rss&utm_campaign=section Latest articles for: Life Sciences Copyright 2025 Â鶹´«Ã½. en-US Fri, 06 Jun 2025 23:04:02 +0000 /lifesciences/articles/2350526?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2350526 Masimo Corp. fought back against founder Joe Kiani's motion to dismiss the company's Delaware Chancery Court suit seeking a declaration that he's not due a $450 million payout after his ouster as CEO, arguing that bid is an "improper attempt to evade" the Delaware court's jurisdiction. Fri, 06 Jun 2025 22:56:46 +0000 /lifesciences/articles/2350693?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2350693 Acting U.S. Patent and Trademark Office Director Coke Morgan Stewart on Friday turned away a series of challenges to Welch Allyn Inc.'s heart monitor patents, determining petitioner iRhythm Technologies Inc. should have disputed them much earlier. Fri, 06 Jun 2025 21:39:50 +0000 /lifesciences/articles/2350391?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2350391 Stablecoin issuer Circle's explosive debut will likely stimulate more crypto listings and possibly jolt the broader pipeline of initial public offerings, capital markets attorneys say. Fri, 06 Jun 2025 21:27:32 +0000 /lifesciences/articles/2349368?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2349368 The U.S. Supreme Court declined Friday to review a decision that telemedicine patents asserted against the U.S. government are invalid for claiming only abstract ideas, in the court's latest refusal to reconsider the standard for determining if inventions are eligible for patents. Fri, 06 Jun 2025 21:03:07 +0000 /lifesciences/articles/2349496?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2349496 Johnson & Johnson health tech unit Biosense Webster's bill in an antitrust trial was upped from $147 million to $442 million after a California federal jury found it stifled competition by conditioning the provision of cardiac mapping services on purchases of cardiac catheters. Fri, 06 Jun 2025 20:45:48 +0000 /lifesciences/articles/2349018?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2349018 A Florida federal judge on Friday denied a bid to toss a pharmaceutical company's lawsuit accusing a rival of stealing trade secrets because its headquarters moved to the Sunshine State after its initial complaint, saying there was "complete diversity at the time of filing of action." Fri, 06 Jun 2025 19:52:39 +0000 /lifesciences/articles/2350480?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2350480 The twice-bankrupt drug store chain Rite Aid is seeking to reassure landlords who filed a spate of objections in recent days that it intends to continue meeting lease obligations despite its move to close some locations. Fri, 06 Jun 2025 19:36:29 +0000 /lifesciences/articles/2350436?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2350436 California-based biotech firm Genentech Inc. has asked a D.C. federal court to recognize a $17.8 million arbitral award against Novartis Pharma AG stemming from a dispute over a licensing agreement for an eye medication. Fri, 06 Jun 2025 19:13:37 +0000 /lifesciences/articles/2350332?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2350332 A Federal Circuit panel on Friday wrestled with its authority to consider arbitration appeals dealing with patent law, with at least one judge appearing skeptical that it could consider Acorda Therapeutics Inc.'s bid to increase a $16.6 million award in a fight with Alkermes PLC over a multiple sclerosis drug. Fri, 06 Jun 2025 18:34:34 +0000 /lifesciences/articles/2350458?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2350458 A New York federal judge on Thursday rebuffed an attempt from CVS Health Corp. to evade responsibility in a False Claims Act case, after a jury found that its subsidiary Omnicare bilked the federal government out of over $135 million in fraudulent drug claims.  Fri, 06 Jun 2025 18:09:06 +0000 /lifesciences/articles/2350352?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2350352 The acting director of the U.S. Patent and Trademark Office revived Longhorn Vaccines & Diagnostics LLC patent claims on Thursday that her predecessor had invalidated to punish Longhorn for misconduct. Fri, 06 Jun 2025 17:42:26 +0000 /lifesciences/articles/2350062?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2350062 Information sharing among competing firms has recently faced dramatic changes in antitrust agency guidance, while courts grapple with the permissible scope of pricing algorithms, leaving companies in limbo, but potential Trump administration changes could offer some reprieve, say attorneys at Axinn. Fri, 06 Jun 2025 17:11:48 +0000 /lifesciences/articles/2348647?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2348647 ​Two recent settlements highlight how whistleblowers and the U.S. Department of Justice have been utilizing the False Claims Act to allege fraud predicated on violations of cybersecurity standards — timely lessons given new bipartisan legislation introducing potential FCA liability for artificial intelligence use, say​ attorneys Rachel Rose and Julie Bracker. Fri, 06 Jun 2025 17:09:27 +0000 /lifesciences/articles/2349947?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2349947 Exelixis has beaten back a challenge to one of its patents covering the blockbuster drug Cabometyx after the Patent Trial and Appeal Board denied Azurity Pharmaceuticals' request to review the patent. Fri, 06 Jun 2025 16:59:09 +0000 /lifesciences/articles/2349815?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2349815 After the Ninth Circuit recently held that four Chinese state-controlled companies were not immune from criminal indictment for alleged economic espionage, foreign sovereign-controlled entities should assess whether their operations and affiliation with their parent states qualify for sovereign immunity under the common law, say attorneys at Cleary. Fri, 06 Jun 2025 16:04:00 +0000 /lifesciences/articles/2342370?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2342370 As the administration targets diversity, equity and inclusion efforts and law firms consider pulling back from their programs, lawyers who care about racial equity and justice can employ four strategies to create microspaces of justice, which can then be parlayed into drivers of transformational change, says Susan Sturm at Columbia Â鶹´«Ã½ School. Fri, 06 Jun 2025 14:48:14 +0000 /lifesciences/articles/2350356?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2350356 Honeywell is taking aim at a Canadian company that has allegedly pursued nearly 200 infringement lawsuits against various businesses based on the same five patents, saying in a federal complaint that the company is trying to scheme its way into a settlement. Fri, 06 Jun 2025 09:45:55 +0000 /lifesciences/articles/2349524?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2349524 Greenberg Traurig LLP is expanding its technology team, bringing in a Perkins Coie LLP transactions whiz as a shareholder in its San Diego office. Fri, 06 Jun 2025 09:35:26 +0000 /lifesciences/articles/2345427?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2345427 Aideen Brennan, a former mergers and acquisitions and private equity senior managing associate at Sidley Austin, has joined Mayer Brown's global corporate and securities practice as a partner in New York. Thu, 05 Jun 2025 22:18:49 +0000 /lifesciences/articles/2349847?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2349847 More than a dozen Republican attorneys general challenging a Biden-era rule that protected gender-affirming care under the Affordable Care Act said the U.S. Department of Health and Human Services can't keep the rule on the books just because the new administration is unlikely to enforce it.